Macro Group Pharmaceutical S.A.E.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. carries a market capitalization of 4.11B, placing it among publicly traded companies globally. Its enterprise value stands at 3.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. has 3.42B shares outstanding.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. trades at a trailing price-to-earnings ratio of 18.63. The price-to-sales ratio is 2.89, and the price-to-book ratio stands at 5.00.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. trades at an EV/EBITDA multiple of 17.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.38 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.68B versus a market cap of 4.11B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. maintains a current ratio of 2.75, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.09, indicating elevated leverage, while an interest coverage ratio of 8.35 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Macro Group Pharmaceutical S.A.E. posted a return on equity (ROE) of 35.97, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 16.78, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 28.57, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.42 indicates how many times Macro Group Pharmaceutical S.A.E. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Macro Group Pharmaceutical S.A.E. recorded 26.11M in income tax expense. That works out to an effective tax rate of 13.59, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 192.07M, leaving 165.79M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Macro Group Pharmaceutical S.A.E.'s stock has gained approximately 74.99% over the past 52 weeks. The 50-day moving average sits at 1.54, while the 200-day moving average is 1.36.

Over the twelve months ended June 30, 2026, Macro Group Pharmaceutical S.A.E. generated 1.07B in revenue and converted that into 165.79M in net income, yielding earnings per share of 0.06. EBITDA reached 210.77M, while operating income came in at 189.68M.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. holds 479.90M in cash and equivalents against 50.03M in total debt, resulting in a net debt position of -479.90M. Total book value stands at 821.53M, with working capital of 707.15M providing operational flexibility.

Macro Group Pharmaceutical S.A.E. produced -24.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.44M in capital expenditures, free cash flow totaled -34.69M - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Macro Group Pharmaceutical S.A.E. posted a gross margin of 70.07, reflecting its pricing power and cost economics. The operating margin of 17.74 and net profit margin of 15.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.67, meaning Macro Group Pharmaceutical S.A.E. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Macro Group Pharmaceutical S.A.E.'s most recent stock split took place on November 16, 2025 with a 53:243 split ratio.

As of June 30, 2026, Macro Group Pharmaceutical S.A.E. has an Altman Z-Score of 7.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.